

DESCRIPTION


Species Reactivity	Human
Specificity	Detects synthetic peptide (aa 706-721) from human VEGFR1/Flt-1 Variant Flt1-14 in direct ELISAs.
Source	Monoclonal Mouse IgG _{2B} Clone # 611926
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Human VEGFR1/Flt-1 Variant Flt1-14 synthetic peptide Glu706-Leu721 Accession # ACA62948
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	2 µg/mL	See Below

DATA



PREPARATION AND STORAGE

Reconstitution	Sterile PBS to a final concentration of 0.5 mg/mL.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Human VEGFR1/Flt-1 is a type I transmembrane receptor for the angiogenic cytokine, VEGF. Alternate splicings of human VEGFR1 mRNA encode soluble, secreted isoforms that can function as inhibitors of VEGF. One, designated sFlt1-14 or sFlt1-e15a, encodes a 733 amino acid (aa), 95-135 kDa form that is produced by non-endothelial cells, notably by degenerative syncytiotrophoblasts within syncytial knots in the placenta. This form appears to be unique to primates and is produced in excess during preeclampsia of pregnancy. The peptide used as an immunogen is not present within either the full-length or alternate secreted forms of the protein.